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a b s t r a c t
Macrophage presence within atherosclerotic plaque is a feature of instability and a risk factor for
plaque rupture and clinical events. Activated macrophages express high levels of the translocator
protein/peripheral benzodiazepine receptor (TSPO/PBR). In this study, we investigated the potential
for quantifying plaque inﬂammation by targeting this receptor. TSPO expression and distribution
in the plaque were quantiﬁed using radioligand binding assays and autoradiography. We show
that cultured human macrophages expressed 20 times more TSPO than cultured human vascular
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smooth muscle cells (VSMCs), the other abundant cell type in plaque. The TSPO ligands [ H](R)-
1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3-isoquinoline carboxamide ([3H](R)-PK11195) and
[3H]N-(2,5-dimethoxybenzyl)-N-(5-ﬂuoro-2-phenoxyphenyl)acetamide ([3H]-DAA1106) bound to the
same sites in human carotid atherosclerotic plaques in vitro, and demonstrated signiﬁcant correlation
with macrophage-rich regions. In conclusion, our data indicate that radioisotope-labelled DAA1106 has
the potential to quantify the macrophage content of atherosclerotic plaque.acrophage
nﬂammation
. Introduction
Atherosclerosis is a chronic inﬂammatory disease of the arterial
all. Vulnerable or rupture-prone plaques are usually identiﬁed
fter clinical events such as myocardial infarction or stroke have
ccurred [1]. Macrophages are prominent in ruptured plaques
uggesting that inﬂammation is a marker of vulnerability [2].
nﬂammation is difﬁcult to quantify with current imaging tech-
iques (angiography, CT, MRI), which focus on the degree of
tenosis rather than the composition of the atherosclerotic plaque.
Positron emission tomography (PET) imaging has the potential
o selectively target andquantify inﬂammatorycellsnon-invasively
ith appropriate ligands. [18F]-ﬂuorodeoxyglucose (FDG) can
uantify carotid artery inﬂammation accurately [3–6], but is taken
pavidly by themyocardium, so for coronary artery atherosclerosis
maging there is a need for radiotracers that are more selective for
acrophages. The translocator protein/peripheral benzodiazepine
∗ Corresponding author at: Box 65,Wolfson Brain Imaging Centre, Addenbrooke’s
ospital, Cambridge CB2 0QQ, United Kingdom. Tel.: +44 1223 746463;
ax: +44 1223 331826.
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Open access under CC BY-NC-ND license.© 2009 Elsevier Ireland Ltd. 
receptor (TSPO/PBR) is highly expressed in the macrophage [7].
A number of ligands have been developed for the TSPO and the
isoquinoline carboxamide PK11195 has been extensively charac-
terised [8,9]. However, for in vivo imaging PK11195 demonstrates
a low signal-to-noise ratio and high levels of non-speciﬁc bind-
ing [9–11]. The aryloxyanilide family of PBR-selective ligands [12]
demonstrate superior binding characteristics for the TSPO [13]. In
our study, we have evaluated the potential of both PK11195 and
DAA1106 in the quantiﬁcation of TSPO expression in the human
atherosclerotic plaque.
2. Materials and methods
2.1. Ex vivo plaque collection and processing
Atherosclerotic plaques were obtained from six patients under-
going carotid endarterectomy (mean age ±SD 69 years ±2.8; range
Open access under CC BY-NC-ND license.64–72years, 5males and1 female) andprocessedblinded topatient
demographics. Tissue sections of 30mwere frozen at −70 ◦C until
required. All patients gavewritten, informed consent and the study
was approved by the regional research ethics committee in Cam-
bridge, UK.
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Table 1
Comparison of TSPO receptor binding characteristics on activated, blood-derived
macrophages and vascular smooth muscle cells. Receptor binding assays were per-
formed with [3H](R)-PK11195 as previously described in Section 2.
Cell type Dissociation
constant (KD) (nM)
Receptor number
(Bmax) (fmol/mg)
type and had more extensive, punctuate expression in CD68-rich
regions (supplementary data, Figs. 1–6H). The relative propor-
tions of these two activation markers varied considerably between
plaques.
Table 2
Correlation of [3H](R)-PK11195 and [3H]-DAA1106 binding with CD68 expression.
Speciﬁc binding of [3H](R)-PK11195 and [3H]-DAA1106 were derived as previously
described. CD68 microscopy images were digitized and co-registered to autoradio-
graphy images. Quantiﬁcation of speciﬁc PK11195 and DAA1106 binding and CD68
immunohistochemical staining in imageswas performedusingMatLabTM. DAA1106
signal was signiﬁcantly correlated with CD68 expression.
Speciﬁc ligand/epitope expression Mean P value
[3H](R)-PK11195 (DLU) 762927.0 ± 173369.8 <0.05*
[3H]-DAA1106 (DLU) 285294.4 ± 56277.7 <0.005**
CD68 (% area) 17.4 ± 4.7J.L.E. Bird et al. / Athero
.2. Binding assay
Receptor binding assays were performed on cultured,
ipopolysaccharide-activated human blood-derived monocytes
nd cultured human VSMCs explanted from healthy arteries
14,15]. Brieﬂy, [3H](R)-PK11195 (3.15TBq/mmol, 37MBq/mL)
Amersham Bioscience, Amersham, UK) was used at 1–24nM in
aturation experiments. Saturation curves and Scatchard plots
ere generated from three separate experiments to produce
alues for receptor density (Bmax) and the dissociation constant
KD) (PRISM software, Graphpad Software Inc., La Jolla, CA,
SA).
.3. Autoradiography
Fresh frozen tissue sectionswere processed for receptor autora-
iography. Sequential sections were incubated in [3H](R)-PK11195
r [3H]-DAA1106 (2.81TBq/mmol, 74MBq/mL) (Amersham Bio-
cience, Amersham, UK) according to published techniques [14].
rieﬂy, tissue sections were incubated in 5nM [3H](R)-PK11195
r 0.25nM [3H]-DAA1106 for 50min. Non-speciﬁc binding was
etermined by the inclusion of 10M unlabelled ligand. Tissue
ections and a tritium standard (Amersham Bioscience, Amer-
ham, UK)were exposed to autoradiography screens for 7–14 days,
maged using a phosphor imager (PerkinElmer Inc., Waltham, MA,
SA) and analysed with OptiQuant software (Packard Instruments
o., Meriden, CT, USA). Regional radioactivity was standard-
sed using tritium standards (Amersham Bioscience, Amersham,
K).
.4. Planimetry
Speciﬁc binding images were generated by automatically co-
egistering non-speciﬁc binding images to total binding images
sing VTK Cisg Registration Toolkit (VTKCisg, London, UK), then
ubtracting the non-speciﬁc binding images from total binding
mages using a MatLabTM script (MathWorks Inc., Cambridge, UK).
uantiﬁcation of speciﬁc PK11195 andDAA1106 binding and CD68
mmunohistochemical staining in images was performed using
atLabTM.
.5. Immunohistochemistry
Immunohistochemical staining was performed on adjacent sec-
ions using the EnVision systemTM (Dako, Ely, UK). Macrophages
ere identiﬁed using an antibody to CD68 and non-speciﬁc
xpression was assessed by replacing CD68 antibody with isotype-
peciﬁc IgG antibody in the absence of counterstain to facilitate
lanimetry. Activated pro-inﬂammatory and alternatively acti-
ated macrophages were identiﬁed using antibodies against
umour necrosis factor receptor type 1 (TNFR1) and CD163, respec-
ively.
.6. Statistics
Results are expressed as means and standard errors (SEM). The
igniﬁcance of correlations between samples was calculated using
pearman’s  with SPSSTM software (SPSS Inc., Chicago, IL, USA).
tatistical signiﬁcance was set at the 5% level.
. ResultsUsing [3H](R)-PK11195 (the most extensively characterised
SPO ligand) we characterised TSPO expression on the two most
bundant cell types present in the atherosclerotic plaque, VSMCs
nd macrophages. A high afﬁnity binding site for PK11195 wasMacrophages 3.656 ± 1.145 8,836 ± 841.2
VSMCs 5.49 ± 0.618 417.4 ± 16.3
Values expressed as mean± SEM; n=3.
identiﬁed on both blood-derived, activated macrophages and
VSMCs; this site was 20-fold more abundant on the macrophages
(Table 1, Fig. 1A and B).
The spatial localisation of [3H](R)-PK11195 and [3H]-DAA1106
binding to human atherosclerotic plaques was determined in
vitro. Speciﬁc binding sites for [3H](R)-PK11195 and [3H]-DAA1106
(Fig. 1C andD and supplementary data Figs. 1–6A and B)were iden-
tiﬁed by subtraction of the non-speciﬁc binding images from the
paired total binding images. Speciﬁc binding in these areas was
quantiﬁed by measuring pixel intensity. PK11195 and DAA1106
signal demonstrated a signiﬁcant correlation (r=0.828, p=0.041)
(Table 2).
The expression of the macrophage marker CD68, was deter-
mined in adjacent tissue sections and demonstrated a punctuate
pattern in the shoulder and cap regions (Fig. 1E; supplementary
data, Figs 1C and 2C, inset regions) which was absent in iso-
type IgG control sections (Fig. 1F) and co-localised with both
PK11195andDAA1106 speciﬁc binding.Quantiﬁcationof CD68 sig-
nal by planimetry enabled correlation with speciﬁc PK11195 and
DAA1106 binding. The necrotic core of someplaques demonstrated
CD68 expression (e.g. supplementary data, Figs. 2 and 3, arrowed
regions) in the absence of IgG isotype control signal; these did not
demonstrate speciﬁc [3H](R)-PK11195 and [3H]-DAA1106 binding.
This was anticipated, because neither ligand could be expected
to bind to dead cells. Adjacent tissue sections were stained with
haematoxlyin and eosin (data not shown) to facilitate delineation
of the necrotic core by blinded visual assessment. Exclusion of the
necrotic core region from the CD68, PK11195 and DAA1106 images
resulted in a signiﬁcant correlation between DAA1106 and CD68
expression (r=0.94,p=0.0048)butnotbetweenPK11195andCD68
(r=0.657, p=0.156).
TNFR1 is expressed in inﬂammatory macrophages and this
receptor was present in CD68-rich regions, although with gen-
erally low expression levels (supplementary data, Figs. 1–6G).
CD163 is a marker of alternatively activated macrophage pheno-[3H](R)-PK11195 and [3H]-DAA1106 values are presented as digital luminescence
units (DLU).
* Signiﬁcant correlation with [3H]-DAA1106 signal.
** Signiﬁcant correlation with CD68 expression. Values expressed as mean± SEM;
n=6.
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Fig. 1. Quantiﬁcation of translocator protein (TSPO) in cultured cells, with co-localisation of TSPO and macrophage presence in a carotid endarterectomy tissue section
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. Discussion
In this study we have shown for the ﬁrst time that the in vitro
peciﬁc bindingof [3H]-DAA1106 inhumanatherosclerotic plaques
emonstrates the same topography as that of [3H](R)-PK11195.
e also demonstrate that TSPO/PBR expression in cultured human
acrophages is considerably higher than in VSMCs. In addition,
fter exclusion of redundant necrotic cores from analysis, we
how a signiﬁcant correlation between macrophage presence in
he ﬁbrous cap and the binding of [3H]-DAA1106. These ﬁndings
ndicate that TSPO expression in plaque macrophages represents
potential target for the in vivo quantiﬁcation of carotid plaque
nﬂammation using non-invasive PET scintigraphy.ured, blood-derived monocytes (A) and vascular smooth muscle cells (B). Speciﬁc
nd non-speciﬁc binding were obtained by autoradiography and speciﬁc binding
ical staining of macrophages with antibody to CD68 (E). Microscopy images were
pe-speciﬁc IgG antibody) showed negligible staining (F). Bar =1mm.
The derivation of TSPO receptor binding data from atheroscle-
rotic plaques is problematic due to the size of lesion and
heterogeneous mix of cells. Therefore, we quantiﬁed TSPO expres-
sion on cultured cell populations using PK11195 which is the best
characterised TSPO ligand. Mature macrophages were produced
from blood-derived monocytes. The density of TSPO expression
(Bmax) on these macrophages was approximately 20-fold higher
than that on VSMCs, demonstrating considerable discrimina-
tion between the two major cell types present in the plaque.
Both cell types had a single, high afﬁnity binding site consis-
tent with the presence of the TSPO receptor, supporting the
study of Fujimura et al. [16]. Fujimura calculated a TSPO abun-
dance (Bmax) of 1.6 pmol/mg protein in intact, in vitro atheroma,
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[16] Fujimura Y, Hwang PM, Trout H, et al. Increased peripheral benzodiazepineJ.L.E. Bird et al. / Athero
sing a KD value of 18nM derived from cultured human blood
onocytes [10]. This Bmax value lies between our values for
he two cell types and is consistent with a mixed population
f high (macrophage) and low (VSMC) TSPO expressing cells
Table 1).
PK11195 has previously shown some binding in the necrotic
ore of human plaques (data not shown) and poor discrimina-
ion between murine inﬂamed and stable atherosclerotic plaques
17], suggesting poor in vivo binding. Thus, there is a need for
SPO ligands with high selectivity for the TSPO and a lower
on-speciﬁc binding. The aryloxyanilide family of TSPO-selective
igands [12] have superior TSPO binding characteristics compared
o PK11195 [13]. In our study, PK11195 andDAA1106 speciﬁc bind-
ng and CD68 expression were assessed on sequential sections.
K11195 and DAA1106 speciﬁc binding had statistically signiﬁ-
ant topographical co-incidence within each plaque, which was
argely restricted to the shoulder and cap regions. Thus, both lig-
nds demonstrated selectivity towards TSPO in macrophage-rich
egions.
The plaques used in this study had considerable morpholog-
cal heterogeneity. The macrophage-speciﬁc protein CD68 was
resent as punctuate foci in the shoulder and cap regions of the
arotid plaques. Where punctuate CD68 expression was present
n the necrotic core of some plaques, these regions also exhib-
ted speciﬁc binding of PK11195 and DAA1106. In other plaques,
diffuse expression was present which did not exhibit spe-
iﬁc radioligand binding, suggesting that this was not related
o viable macrophages. IgG isotype control binding was min-
mal in all the necrotic cores examined. Examination of the
acrophage phenotype suggested the presence of both classically
ctivated, pro-inﬂammatory macrophages (TNFR1 expression) and
lternatively activated, anti-inﬂammatory macrophages (CD163
xpression). CD163 is associated with the clearance of proinﬂam-
atory haemoglobin and the resolution of wound inﬂammation
hrough production of IL-10. Thus, the presence of CD163 expres-
ion in these plaques is consistent with resolution of inﬂammation
fter rupture of the plaque. The relative proportions of these two
arkers varied considerably between plaques, consistent with dif-
erences in time between plaque rupture and surgical removal of
he plaque at endarterectomy. The impact of macrophage activa-
ion phenotype or differentiation (macrophages are the precursors
f foam cells) on TSPO expression is currently unknown. The
tatistically signiﬁcant correlation between CD68 and DAA1106
peciﬁc binding and the superior selectivity and binding afﬁnity
f DAA1106 for the TSPO suggest that this ligand should per-
orm better in quantifying macrophage abundance by PET imaging
n a clinical setting. The presence of both pro-inﬂammatory and
nti-inﬂammatory macrophage phenotypes in these plaques high-
ights a potential drawback in the validation of PET ligands using
x vivo human clinical tissue. Further validation of this ligand for
maging the pre-rupture inﬂammatory phase of atherosclerosis is
uggested, using preclinical models of disease with predictable
orphology and pathogenesis.
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